MedPath

Application of Diffusion Tensor Imaging and Tractography in Epilepsy Surgery

Not Applicable
Conditions
Temporal Lobe Epilepsy
Registration Number
NCT02590419
Lead Sponsor
Andrew Parrent
Brief Summary

Using Synaptive Medical's BrightMatter™ products to better visualize and plan epilepsy surgeries by considering white matter tracts, and considering whether the technology results in improved clinical outcomes.

Detailed Description

A common goal of focal brain resection is the removal of a lesion while preserving healthy eloquent tissues of the brain. One such eloquent area that is commonly aimed to be preserved are the white matter nerve fiber tracts which is critical of brain communication and function. This study aims to investigate whether the use of Synaptive Medical's BrightMatterTM technology can help neurosurgeons to better visualize and plan surgeries by considering the white matter tracts, and whether it results in improved clinical outcomes. This study will investigate the preservation of the optic radiations in anterior temporal lobectomy epilepsy surgeries.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patients diagnosed with temporal lobe epilepsy between 18 and 65 years of age.
  • Patients whose seizures are disabling and/or are not controlled by any form of epileptic medication.
  • Patients whose clinical pre-surgical investigations indicates the need for anterior temporal lobe resection (ATLR).
Exclusion Criteria
  • Prior resective epilepsy surgery.
  • Past or planned non resective epilepsy surgery (such as a corpus callosotomy and vagal nerve stimulator placement).
  • Contraindication to MRI, and/or whom are (or suspect to) being pregnant.
  • Complicated medical problems such as cancer or heart disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Resection ZoneAssessed at surgical visit

Identification of resected region

Total volume of tract damageAssessed between pre and post-operative visits (6 month follow-up).

Tract damage

Post-operative visual field testingAssessed at post-operative visit (6 month follow-up)

Outcome will be measured using a routine visual field testing procedure known as the Humphrey and Estermann perimetry test.

Secondary Outcome Measures
NameTimeMethod
Quality of life assessmentAssessed during surgical visit up to 26 weeks.

Measured using a standard epilepsy questionnaire known as the WHOQOL-BREF questionnaire (World Health Organization Quality of Life Assessment (WHOQOL-BREF))

Total neurological planning timeAssessed during planning phase of surgery, between both pre and post-operative visits (6 month follow-up).

Measured in hours

Total OR timeAssessed during surgical visit

Measured in hours

Total cost of surgeryAssessed through study completion, an average of 1 year.
Duration of hospital stayAssessed during surgical visit up to 26 weeks.

Measured in # of days

Number of seizure free daysAssessed between surgical date until post-operative visit (6 month follow-up).

Measured in # of days

Functional impairmentAssessed during surgical visit up to 26 weeks.

Measured using a routine functional impairment test known as the Karnofsky performance scale

Morbidity and complicationsAssessed through study completion, an average of 1 year.

Number of cases

Seizure control after surgeryAssessed at surgical visit up to 26 weeks.

Assessed using a routine seizure control test known as the Engel score, assessed by a neurologist/epileptologist

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.